Paris 8èmes journées de la SFSPM et 4èmes de la SIS

1986  8èmes journées de la Société Française
  de Sénologie et de Pathologie Mammaire
  couplé au 4ème congrès de la
  Société Internationale de Sénologie,
  septembre 1986
  Masson, Paris

 

 1. THEME I – DIAGNOSTIC ET TERMINOLOGIE DES MALADIES DU SEIN
TOPIC I – DIAGNOSIS AND TERMINOLOGY OF BREAST DISEASES
 
Mardi 2 septembre – Tuesday September 2 1
Prebiopsy localization of non palpable breast lesions, S. FEIG, G. SCHWARTZ ………  
Aspect mammographique du carcinoma lobulaire infiltrant, M. LE GAL 6
Ductal carcinoma in situ and lobular carcinoma in situ : definition and diagnosis, P.P. ROSEN 7
Breast imaging : magnification mammography, diaphanography, CT scanning, heavy-particle mammography, and MR imaging 10
Sur et sous-estimation du diagnostic de malignité en histopathologie mammaire, M. TROJANI, I. DE MASCAREL, J.M. COINDRE 15
Cancers infracliniques du sein. A propos de 83 cas, J.M. TUBIANA, B. DUPERNAY, I. MOROT, L. THONEL, Ch. DRUMLEWICZ 19
Merceredi 3 septembre – Wednesday September 3  
La mammographie digitale, M. COLLARD (texte non parvenu – Not received)  
Three dimensional reconstruction in mammography, W. GORDENNE, F. MALCHAIR,J. DESTINE 23
Microcalcifications : differential diagnosis, M. LANVI 25
Radial scar. Definition, Relationsphip to breast carcinoma, F. LINELL, O. LJUNGBERG 26
Breast ultrasound examination, E.A. SICKLES 28
Galactography and pneumocystography, L. TABAR 30
MRI in breast tumors, D. VANAL, J. MASSELOT, G. CONTESSO, D. CASTAIGNE,D.SARRAZIN 31
 2. THEME II – HORMONES ET MALADIES DU SEIN
TOPIC II – HORMONES AND BREAST DISEASES
 
Mardi 2 septembre – Tuesday September 2 32 
Mécanisme d’action des anti-oestrogènes dans les cancers du sein, J.L. BORGNA,H. ROCHEFORT  
Prolactin receptors in normal and neoplastic mammary cells, J. DJANE, P.A. KELLY,J.P. PEYRAT, I. DUSANTER-FOURT, M. KATDH 37
Estrogenic regulation of human breast cancer, M.E. LIPPMAN, R.B. DICKSON, E.P. GELMANN, A . KASID, S. BATES, C. KNABBE, S.M. SWAIN, M. McMANAWAY, G. WILDING, N. DAVIDSON, K. HUFF, D. BRONZERT 41
Progrès récents dans l’étude de l’action des hormones stéroïdes, E. MILGROM,H. LOOSFELT, M. ATGER, F. LOGEAT, M. APPLANAT, A. BAILLY (texte non parvenu) – Not received)  
Oestrogen production and metabolism by human breast tumours, W.R. MILLER 44
Intérêt clinique de la mesure des récepteurs des stéroïdes : le point de 1986, S. SACZ 49
Mercredi 3 septembre – Wednesday September 3 235
Immunocytochemical localization of progeserone receptor in human breast cancers, M.PERROY-APPLANAT, M.T. GROYER-PICARD, F. LORENZO, A. JOLIVET,M.T. VU AHI, C. PALLUD, F. SPYRATOS, E. MILGROM  
Immunochemical analyses of steroid receptors in breast cancer, G.L. GREENE, M.F. PRESS 55
Interaction des récepteurs hormonaux ave le DNA, B. GRONER (texte non parvenu –Not received)  
Epithelial-stromal interactions in mammary gland development, K. KRATOCHWIL 59
Monoclonal anbibodies against progesterone receptor, F. LOGFAT, M. PERROT-APPLANAT, H. LOOSFELT, A. JOLIVET, F. LORENZO, E. MILGROM 61
Early studies of LH-RH action in breast cancer, R.I. NICHOLSON, K.J. WALKER,A. TURKES, J. DYAS, P.N. PLOWMANN, M. WILLIAMS, R.W. BLAMEY 62
Autocrine regulation of breast cancer cell growth by the estrogen-induced 52K protein,
F.VIGNON, F. CAPONY, M. CHAMBON, G. FREISS , M. GARCIA, M. MORISSET,H. ROCHEFORT
67
 3. THEME III – EPIDEMOLOGIE ET DEPISTAGE
TOPIC III – EPIDEMOLOGY AND SCREENING
 
Mercredi 3 septembre – Wednesday Septembre 3
Screening tests for breast cancer, J. CHAMBERLAIN, R. ELLMAN
70
Nutrition et cancer du sein, F. DE WAARD 72
Benefit and risk considerations in screening, S. FEIG 76
Oral contraceptives and breast cancer : a selective review of literature, A. KALACHE,M. CALEFFI 81
Exogenous estrogens and breast cancer, J. KELSEY 88
Contraceptifs oraux et cancer du sein : résultats d’une étude cas-témoins française, M.G. LE, A. BACHELOT 90
Jeudi 4 septembre – Thursday September 4 91
Diet in the epidemiology of breast cancer, S. GRAHAM  
Non-dietary risk factors for breast cancer, J. KELSEY 96
Genetics and breast cancer, H. LYNCH, J. MARCUS, J. LYNCH, P. SHEA, G. SCHUELKE, R. CALLAHAN, A. THOR, J. SCHLOM 102
Conclusions of the UICC project on screening for breast cancer, A.B. MILLER, N.E. DAY, C.J. BAINES, J. CHAMBERLAIN, M. HAKAMA, P. PROROK 236
Descriptive epidemiology of breast cancer, C.S. MUIR, A.S. DONN, P. BOYLE 102
The results of periodic one-wiew mammography screening in a randomised controled trial in Sweden. Part I, I.G. FAGERBERG, L. BALDETORP, O.GRÖNTOFT, J. MANSON 104
The results of periodic one-view mammography screaning in a randomized controled Trial in Sweden part II, L. TABAR, A. GAD, L. HOLMBERG, U. LJUNGQUIST 105
 4. THEME IV – MASTOPATHIES BENIGENES ET ETATS PRECANCEREUX
TOPIC IV – BENIGN AND PREMALIGNANT DISEASE OF THE BREAST
 
Mercredi 3 septembre – Wedmesday September 3
Injection percutanée d’un produit de contraste et étude de la vitesse de croissance des fibroadénomes mammaires, C. COLIN
106
Définition et classification, anatomo-pathologique des mastopathies bénignes, G. CONTESSO, G. BERTIN, M.J. LACOMBE 110
Rôle du chirurgien dans le diagnostic et le traitement des tumeurs bénignes, J.C. DURAND 117
Triple diagnosis : clinical, radiological and cytological, G. KREUZER, Th. PARADOWSKI 120
Estrogen and progesterone receptors in benign breast tumors and lesions : relationship with histological and cytological feature, M.J. LACOMBE, C. GIANI, E. D’AMORE,J.C. DELARUE, H. MOURIESSE, F. MAY-LEVIN, H. SANCHO-GARNIER,G. CONTESSO 123
Hormonal therapy of benign breast disease, P. MAUVAIS-JARVIS, R. SITRUK-WARE 128
Mastopathies bénignes et risque de cancer du sein chez la femme. Etude coopérativerétrospective des Centres de Lutte contre le Cancer. Rapporteur : C. PALLUD 133
Jeudi 4 septembre – Thursday September 4
Estradiol and progesterone interaction on normal and pathological breast tissue, F.KUTTEN, C. MALET, A. GOMPEL, P. SPRITZER, S. FOURNIER, G. CHOMETTE, P. MAUVAIS-JARVIS
136
Histogenetic theories of breast carcinoma, F. LINELL, O. LIUMBERG 141
New morphological methods in the study of benign mastopathies, A. LLOMBART-BOSCH, F. VERA-SEMPERE, M. GONZALES-DEUFSA, C. CALABUIG, M. PEREZ-BACETTE, A. PEYDRO-OLAYA 144
Flow cytometry of breast cancer, M.R. MELAMED 147
The proliferative breast disease concept and risk factors for carcinoma, L. OZZELIO 148
New entities with potential precancerous significance, P.P. ROSEN 150
 5. THEME V – BIOLOGIE NON HORMONALE DES MALADIES DU SEIN
TOPIC V – NON HORMONAL BIOLOGY OF BREAST DISEASES
 
Mardi 2 septembre – Tuesday September 2 154
Human endogenous retroviral genes and proto-oncogenes in breast carcinomas, R . CALLAHAN,I. ALI, M.H. CHAMPENE, C. ESCOT, J. GEST, R. LIDEFREAU,J. SCHLOM, C. THEILLET  
Milk proteins : differentiation markers in breast pathology, J. COLLETTE, V. LE DOUSSAL, J.R. VAN CAUWENBERGE, F. SPYRATOS, J. HUSYIN, P. FRANCHIMONT 159
GCDFP-16 – a tumor marker of breast carcinoma : serological and immunohistological findings, D. HAAGENSEN, G. MAZDUJIAN, W. DILLEY, S. WELLS 164
Human monoclonal antibodies directed against viral antigens associated with human breast carcinoma, I. KEYDAR, N.I. TSARFATI, E. SAHAR, S. CHAITCIK, Y. SHOENFELD 169
Potential clinical utility of radiolabelled monoclonal antibodies in the management of human breast cancer, F. MORNEX, D. COLCHER, M.O. WEEKS, J. SCHLOM 243
Molecular and immunological analysis of mucin-like molecules from human breast epithelial-cells, J. TAYLOR-PAPADIMITRIOU, J. BURCHELL, S. GENDLER,A. GRIFFITHS 170
Jeudi 4 septembre – Thursday September 4 172
Oncogenes and human Malignancies, S.A. AARONSON  
Le récepteur humain des oestrogènes, P. CHAMBON (texte non parvenu – Not received)  
Invasivité et métastases des cancers du sein, P.M. MARTIN, F. KOPP, J.C. LISSITZKY 173
Host defense mechanisms in breast patients, M. MICKSCHE, R. KOLB, R. JAKESZ, H. RAINER, Ch. DITTRICH, K. MOSER, P. SAGASTER, A. UCHIDA, E. YANAGAWA 248
Biological markers of the human breast and its disorders, A.M. NEVILLE 178
Regulation of normal growth and nooplasia by the EGF-receptor, J. SCHLESSINGER 190
Translation of tumor-associated and proto-oncogene products in buman mammary carcinoma cell population, J. SCHLOM, A. THOR, N. OHUCHI, P. HAND, D. WUNDERLICH, R. MURARO, M. WECKS, D. COLCHER, D. PAGE, C. SZPAK,W. JOHNSTON 181
 6. theme vi – traitements du cancer du sein
topic vi – treatments of breast cancers
 
Mardi 2 septembre – Thesday September 2 186
Adjuvant systemic trials : Tamoxifen postmenoposal cytotoxic, premenopausal ?
C.HILL, R. PETO
 
Neoadjuvant chemotherapy in the conservative management of breast cancers. Study On 205 patients, CI JACQUILLAT, M. WEILI, G. AUCLERC, M. SELLAMI, M.F.AUCLERC, D.KHAYAT, R. PETO 187
Immunologic monitoring and immunotherapeutic reagents : new approaches to the management of breast cancer, D.M. LOPEZ 195
Terminology and pathology of inflammatory breast cancer, P.P. ROSEN 200
Les protocoles de chimiothérapie dans les cancer inflammatoires, J. ROUESSE, T. 
LE CHEVALIER, D. SARRAZIN
202
Clinical significance and staging of non-palpable breast cancer, F.G. SCHWARTZ, 
S.A. FEIG, A.L. ROSENBERG, A.S. PATCHEFSKY
210
Long-term results of quadrantectomy. The Milan trial, U. VERONESI, M. DEL 
VECCHIO, A. LUINI, R. ZUCALI
213
Jeudi 4 septembre – Thursday September 4 215
Current status of Milan adjuvant chemotherapy trials for node-positive and node-
negative breast cancer, G. BONADONNA
 
The state of pre-operative radiotherapy in breast cancer, H. HOST, J. HOIE, 
O.MONGE, H. MELSOM, O. KAALHUS
216
Intraductal breast carcinoma : definition, diagnosis, and prognosis, J. JACQUEMIER,
D.HANS, P. MEYNARD, Y. AYME, J. HASSOUN
219
Radical or conservative surgical treatment of intraductal carcinoma, F. KRAUER, P. SCHÄFER, D. OBRADOVIC 225
The part of reconstructive surgery in the management of the intraductal carcinomas,
M.LEJOUR, R. DEBAEMAECKER, M. JABRI, A. DE MEY, H. EDER, 
J. DUCHATEAU, P. GELINCK, A.DECLETY
226
Adjuvant hormone therapy in operable breast cancer, T.J. POWLES (texte non parvenu – Not received)  
 7. SYMPOSIUM SATELLITE HORMONOTHERAPIE DES CANCERS GYNECOLOGIQUES
SATELLITE SYMPOSIUM HORMONOTHERAPY IN GYNECOLOGIC CANCERS
Laboratoires Upjohn – France
 
Lundi 1er septembre – Monday September 1 229
Intérêt d’une présentation de l’acétate de médroxyprogestérone en comprimés de 200mg. Considérations pharmacocinétiques et cliniques, P. POUILLART, J. PALANGIE, T. DORVAL, M. JOUVE, E. GARCIA-GIRALT  
The biouvailability of the tablet formulation of medroxyprogesterone acetate, provera 200mg, compared with the old tablet formulation, Provera 100mg in healthy malevolunteers, A. BYE 230
Treatment of advanced breast cancer with medroxyprogesterone acetate : a randomized ovaluation of the dose-response relationship to two-dose levels, C. ROSC, C. KAMBY,E.ENGELSMAN, M. NOOT, H.T. MOURIDSEN, R. SYLVESTER, N. ROTMENSZ.. 232
Place de la MPA dans les traitements adjuvants des cancers du sein – Aspects prospectifs, A. BREMOND 233
Hormonothérapie adjuvante par acétate de médroxyprogestérone des carcinomes de l’endomètre, M. BOLA 234

 

 Pour commander cet ouvrage: www.masson.fr